Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They said, he said, I just paid $88 ...

BrightGene Pharmaceutical Co., Ltd., an international, innovation-driven pharmaceutical company, presented data from two Phase 2 studies for BGM0504, its ...

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...